Boyds Acquires New Cambridge Office to Support Rapid Growth
Boyds, the drug development consultancy which helps pharmaceutical companies translate great science into marketable medicines for patient benefit, has relocated into new premises in Cambridge.
The company has invested in excess of £0.5m in the purchase and complete refurbishment of a 1700 sq ft building located at South Cambridge Business Park in Sawston.
Boyds was previously located in Cottenham, a village on the outskirts of the city, and its head office will remain in Crewe, Cheshire.
Professor Alan Boyd, CEO and founder of Boyds said the team had outgrown its former property after a period of swift growth.
He said: “Our team has grown significantly in the last 12 months and we needed more space so we could futureproof our building for further new capacity in the months and years ahead.
“We remain in a prime location, close to academic groups, start-up hubs and industry, with several science parks within a five-mile radius.
“We also now have a dedicated meeting room facility that can support large client meetings and seminars.”
Professor Boyd said Boyds was committed to Cambridge as the city continues to be a thriving scientific hub that is recognised globally for its excellence in innovative research, and can be easily reached from London.
He added: “Cambridge is an ideal location for Boyds as it is optimally aligned with our goal to provide expert consultancy services for clients globally who are focusing on innovative products and treatment approaches.”
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018